Skye Bioscience, Inc.
Statements
Cash Flow
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +421.6% | +49.9% | -46.1% | -80.8% | -5.3% | +28.0% | +1,723.2% | +236.9% | +8.0% | +140.4% | +142.2% | |
| – | +3,746.8% | +70.5% | -13.8% | +10.9% | +0.8% | -55.5% | +187.1% | -27.6% | +57.0% | +742.3% | -6.6% | |
| – | – | – | – | +19,046.1% | -153.1% | – | – | – | – | – | – | |
| – | -183.7% | – | -899.3% | – | +195.1% | -68.1% | +586.8% | -217.8% | – | – | – | |
| – | -91.5% | +460.9% | +76.8% | -77.7% | +64.9% | +0.0% | +1,156.8% | -69.1% | -55.3% | +12,681.1% | -99.6% | |
| – | -91.5% | +460.9% | +76.8% | -77.7% | +64.9% | +0.0% | +1,156.8% | – | +26.5% | -103.7% | +7,839.4% | |
| – | – | – | +0.0% | +369.3% | -99.8% | +10,800.2% | -100.0% | – | – | -100.0% | – | |
| – | +239.6% | -94.0% | +761.7% | +57.7% | +8.4% | +11.6% | +95.2% | -101.6% | – | +408.2% | -100.0% | |
| – | +1,353.7% | -204.7% | – | +716.6% | -101.5% | – | +918.6% | -218.8% | – | +539.1% | -207.7% | |
| – | – | – | – | – | – | – | – | – | – | – | – |
Data as of: September 18, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.